Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3400999 | Enfermedades Infecciosas y Microbiología Clínica | 2014 | 9 Pages |
Abstract
To achieve effective and safe vaccines for the prevention of not yet controlled or re-emergent infectious diseases, one of the more importance aspects is to have immunological adjuvants that allow inducing a protective immune response with an appropriate safety profile. Since 1926 the aluminium compounds have been used as adjuvants for human vaccines, and only in the last 10Â years some new products have been registered. Although there an enormous quantity of proposed candidates, the toxicity is the main factor that has limited their introduction into the clinic. In this work the mechanism of action are updated, and the toxicity of the immunological adjuvants are revised, especially those that have obtained clinical approval or are close to getting it.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
Alexander Batista-Duharte, Miriam Lastre, Oliver Pérez,